Peter M Miller1, Sarah W Book, Scott H Stewart. 1. Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC 29425, USA. millerpm@musc.edu
Abstract
OBJECTIVE: To summarize published data on pharmacologic treatments for alcohol dependence alone and in combination with brief psychosocial therapies that may be feasible for primary care and specialty medical settings. METHODS: We conducted electronic searches of published original research articles and reviews in MEDLINE, SCOPUS, CINAHL, Embase, and PsychINFO. In addition, hand searches of reference lists of review articles, supplemental searches of internet references and contacts with experts in the field were conducted. Randomized controlled studies published between January 1960 and August 2010 that met our inclusion/exclusion criteria were included. RESULTS: A total of 85 studies, representing 18,937 subjects, met our criteria for inclusion. The evidence base for oral naltrexone (6% more days abstinent than placebo in the largest study) and topiramate (prescribed off-label) (e.g., 26.2% more days abstinent than placebo in a recent study) is positive but modest. Acamprosate shows modest efficacy with recently abstinent patients, with European studies showing better results than U.S. ones. The evidence-base for disulfiram is equivocal. Depot naltrexone shows efficacy (25% greater reduction in rate of heavy drinking vs. placebo, in one of the largest studies) in a limited number of studies. Some studies suggest that patients do better with extensive psychosocial treatments added to medications while others show that brief support can be equally effective. CONCLUSIONS: Although treatment effects are modest, medications for alcohol dependence, in conjunction with either brief support or more extensive psychosocial therapy, can be effective in primary and specialty care medical settings.
OBJECTIVE: To summarize published data on pharmacologic treatments for alcohol dependence alone and in combination with brief psychosocial therapies that may be feasible for primary care and specialty medical settings. METHODS: We conducted electronic searches of published original research articles and reviews in MEDLINE, SCOPUS, CINAHL, Embase, and PsychINFO. In addition, hand searches of reference lists of review articles, supplemental searches of internet references and contacts with experts in the field were conducted. Randomized controlled studies published between January 1960 and August 2010 that met our inclusion/exclusion criteria were included. RESULTS: A total of 85 studies, representing 18,937 subjects, met our criteria for inclusion. The evidence base for oral naltrexone (6% more days abstinent than placebo in the largest study) and topiramate (prescribed off-label) (e.g., 26.2% more days abstinent than placebo in a recent study) is positive but modest. Acamprosate shows modest efficacy with recently abstinent patients, with European studies showing better results than U.S. ones. The evidence-base for disulfiram is equivocal. Depot naltrexone shows efficacy (25% greater reduction in rate of heavy drinking vs. placebo, in one of the largest studies) in a limited number of studies. Some studies suggest that patients do better with extensive psychosocial treatments added to medications while others show that brief support can be equally effective. CONCLUSIONS: Although treatment effects are modest, medications for alcohol dependence, in conjunction with either brief support or more extensive psychosocial therapy, can be effective in primary and specialty care medical settings.
Authors: J P Lhuintre; N Moore; G Tran; L Steru; S Langrenon; M Daoust; P Parot; P Ladure; C Libert; F Boismare Journal: Alcohol Alcohol Date: 1990 Impact factor: 2.826
Authors: P M Monti; D J Rohsenow; R M Swift; S B Gulliver; S M Colby; T I Mueller; R A Brown; A Gordon; D B Abrams; R S Niaura; M K Asher Journal: Alcohol Clin Exp Res Date: 2001-11 Impact factor: 3.455
Authors: R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam Journal: JAMA Date: 1986-09-19 Impact factor: 56.272
Authors: Steven M Ornstein; Peter M Miller; Andrea M Wessell; Ruth G Jenkins; Lynne S Nemeth; Paul J Nietert Journal: J Stud Alcohol Drugs Date: 2013-07 Impact factor: 2.582
Authors: Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty Journal: Neuropsychopharmacology Date: 2019-04-10 Impact factor: 7.853
Authors: Kara M Bensley; John Fortney; Gary Chan; Julia C Dombrowski; India Ornelas; Anna D Rubinsky; Gwen T Lapham; Joseph E Glass; Emily C Williams Journal: J Rural Health Date: 2019-01-31 Impact factor: 4.333